🚀 SMFG and Partners Explore Stablecoin Commercialization and Applications
#SMFG #Stablecoin #Commercialization #Applications #Partnership #Blockchain #Finance #Innovation #RegulatoryFramework #MarketInfrastructure
According to PANews, a memorandum of understanding has been signed by Sumitomo Mitsui Financial Group (SMFG), Sumitomo Mitsui Banking Corporation (SMBC), TIS, Ava Labs, and Fireblocks to jointly explore the future commercialization and application of stablecoins. The agreement outlines a collaborative effort to develop a framework for the issuance and circulation of stablecoins, focusing on technological, regulatory, and market infrastructure needs. This initiative extends beyond pilot projects to define specific use cases for stablecoins in commercial applications.
The collaboration will also investigate the potential use of stablecoins as a settlement tool, including their application in the settlement of tokenized financial and real assets, such as government and corporate bonds and real estate.#SMFG #Stablecoin #Commercialization #Applications #Partnership #Blockchain #Finance #Innovation #RegulatoryFramework #MarketInfrastructure
🚀 OpenAI Delays Advertising Plans Amid External Threats to ChatGPT
#OpenAI #AdvertisingPlans #ChatGPT #CodeRed #ProductProtection #ModelSecurity #PlatformStability #Commercialization #ExternalThreats #CompetitiveChallenges
According to PANews, OpenAI's CEO has declared a 'Code Red' in response to external threats facing ChatGPT. The company has decided to postpone its plans to introduce advertising within ChatGPT. Resources will be prioritized towards enhancing product protection and addressing competitive challenges, including improving model security and platform stability. Consequently, the commercialization efforts, including advertising tests, will be delayed.#OpenAI #AdvertisingPlans #ChatGPT #CodeRed #ProductProtection #ModelSecurity #PlatformStability #Commercialization #ExternalThreats #CompetitiveChallenges
🚀 Quantum Computing Commercialization Predicted for Mid-21st Century
#QuantumComputing #Commercialization #Innovation #FutureTech #CathieWood #TechnologyTrends #ARKInvest
ARK Invest founder Cathie Wood has shared insights on the future of quantum computing. According to Odaily, Wood stated that one of the most frequently asked questions about innovation and future trends is related to quantum computing. She noted that extensive research has been conducted on the current stage of quantum computing. Wood predicts that commercial applications related to quantum computing are likely to emerge between the mid-2040s and mid-2060s. Reflecting on her career, she mentioned that the commercialization of quantum computing has always seemed to be '20 years away.' Having been in the field for a considerable time, she now estimates that true commercial applications might still be 19 years away.#QuantumComputing #Commercialization #Innovation #FutureTech #CathieWood #TechnologyTrends #ARKInvest
🚀 Fosun Pharma Grants Eisai Exclusive License for Hansizhuang Commercialization
#FosunPharma #Eisai #exclusiveLicense #Hansizhuang #serplulimab #pharmaceutical #licensingAgreement #upfrontFee #regulatoryMilestones #salesMilestones #royalties #commercialization #globalPartnership #biopharma
Fosun Pharma announced on February 5 that it has entered into a licensing agreement with Japanese pharmaceutical company Eisai Co., Ltd. According to Jin10, the agreement grants Eisai exclusive rights to commercialize the product Hansizhuang® (serplulimab injection) within specified regions and fields. Eisai will pay Fosun Pharma an upfront fee of $75 million, along with regulatory milestone payments totaling up to $80.01 million, contingent upon achieving various regulatory milestones in the designated regions. Additionally, commercial sales milestone payments could reach up to $233.33 million, based on annual net sales levels of the licensed product in the region. Eisai will also pay royalties calculated as a double-digit percentage of the annual net sales of the licensed product in the region.#FosunPharma #Eisai #exclusiveLicense #Hansizhuang #serplulimab #pharmaceutical #licensingAgreement #upfrontFee #regulatoryMilestones #salesMilestones #royalties #commercialization #globalPartnership #biopharma
🚀 Michael Saylor Highlights Bitcoin's Historical Challenge
#Bitcoin #MichaelSaylor #MicroStrategy #cryptocurrency #adoption #technology #history #commercialization #BTC
Michael Saylor, co-founder of MicroStrategy, has pointed out that Bitcoin's main vulnerability lies in its relatively brief 17-year history, rather than any inherent technical or economic issues. According to NS3.AI, Saylor drew parallels between Bitcoin's adoption process and the historical adoption of significant technologies such as electricity and automobiles, which required decades to achieve widespread acceptance. He suggests that Bitcoin is currently in a phase of commercialization, with time being a crucial element for its broader acceptance.#Bitcoin #MichaelSaylor #MicroStrategy #cryptocurrency #adoption #technology #history #commercialization #BTC
🚀 Zhaoke Ophthalmology Anticipates Approval for Eye Medications in China This Year
#ZhaokeOphthalmology #EyeMedications #ChinaApproval #NationalMedicalProductsAdministration #OphthalmicMedications #Commercialization #MarketingExpenses #PersonnelAllocation #OverseasMarkets #LatinAmerica #Brazil #GreaterBayArea #HongKong #Macau #InternationalSales
Zhaoke Ophthalmology is currently seeking approval from China's National Medical Products Administration for the commercialization of three ophthalmic medications. According to Ming Pao, Chairman and Executive Director Li Xiaoyi expressed optimism about receiving approval within this year, paving the way for commercialization. Prior to this, Li anticipates a significant increase in marketing and promotional expenses, along with personnel allocation.
Li also disclosed plans to expand into overseas markets, with expectations to generate revenue starting in 2028 following overseas registration and approval. The company aims for international sales to eventually constitute half of its total revenue, with a strategic focus on entering the Latin American market, particularly Brazil.
Additionally, Zhaoke Ophthalmology has initiated registration processes for its products in Hong Kong and Macau, aiming for broader application within the Greater Bay Area.#ZhaokeOphthalmology #EyeMedications #ChinaApproval #NationalMedicalProductsAdministration #OphthalmicMedications #Commercialization #MarketingExpenses #PersonnelAllocation #OverseasMarkets #LatinAmerica #Brazil #GreaterBayArea #HongKong #Macau #InternationalSales